Frontiers in Immunology · 2021 · 11 citations · 28 references
MedicineImmunologyOncologyAdaptive ImmunityCancer ImmunologyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyDendritic Cell BiologyOncolytic Virus ImmunotherapyOncolytic Virus TherapyT Cell Responses To TumorsAdaptive Antitumor ImmunityAntigen Presenting CellsAntitumor Immune ActivationIntratumoral AdministrationMelanoma ImmunotherapyMelanoma-associated AntigensTalimogene LaherparepvecTumor Immunogenicity
T-VEC, a HSV-1 derived oncolytic virus, is approved for the treatment of advanced melanoma. The mechanisms that underly the systemic anti-tumor effect that is seen following intratumoral injection have not yet been studied but are likely to be mediated by myeloid dendritic cells (myDC) that initiate an adaptive immune response. In this study we could demonstrate that T-VEC is non-toxic for human myDC. T-VEC and a T-VEC oncolysate of melanoma cell lines were able to mature human myDC. myDC were able to take up lysed melanoma cells and cross-present melanoma-derived tumor antigens to antigen-specific T cells. Our results support the possible role of myDC as mediators of an adaptive anti-tumor effect and intratumoral co-administration of T-VEC plus autologous myDC could be a complementary treatment option. A clinical trial that investigates this hypothesis is currently ongoing.
28
HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2
Man Yu, Haichao Wang, Aihao Ding et al. · Shock · 2006 · 826 citations
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Mikhail Binnewies, Adriana M. Mujal, Joshua L. Pollack et al. · Cell · 2019 · 618 citations · Full text
Life Sciences, Immunology, Oncology +12